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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYWe generated a RUNX2-yellow fluorescent protein (YFP) reporter system to study osteogenic development from human embryonic stem
cells (hESCs). Our studies demonstrate the fidelity of YFP expression with expression of RUNX2 and other osteogenic genes in hESC-
derived osteoprogenitor cells, as well as the osteogenic specificity of YFP signal. In vitro studies confirm that the hESC-derived YFP+ cells
have similar osteogenic phenotypes to osteoprogenitor cells generated from bone-marrow mesenchymal stem cells. In vivo studies
demonstrate the hESC-derived YFP+ cells can repair a calvarial defect in immunodeficient mice. Using the engineered hESCs, we moni-
tored the osteogenic development and explored the roles of osteogenic supplements BMP2 and FGF9 in osteogenic differentiation of
these hESCs in vitro. Taken together, this reporter system provides a novel system to monitor the osteogenic differentiation of hESCs
and becomes useful to identify soluble agents and cell signaling pathways that mediate early stages of human bone development.INTRODUCTION
Human embryonic stem cells (hESCs) provide an attractive
alternative cell source for bone regeneration. Although re-
cent reports demonstrated methods to generate osteogenic
cells from hESCs (Arpornmaeklong et al., 2010, 2011; Ma-
teizel et al., 2008), it is difficult to evaluate the osteogenic
development of hESCs and to identify specific cell popu-
lations based on surface antigen phenotypes, especially
when surface antigens are not cell lineage specific. Also, as-
sessing the homogeneity of cells during differentiation can
be challenging. Therefore, a more efficient monitoring sys-
tem is desirable to evaluate the osteogenic development of
hESCs.
RUNX2 is known as a critical regulator (Komori, 2010;
Maruyama et al., 2007; Sudhakar et al., 2001) during
osteogenic development. RUNX2 plays an essential role
upstream of osteoblastic differentiation in osteogenic
specification (Hill et al., 2005), and it induces the expres-
sion of osteogenic extracellular matrix genes during oste-
oblast maturation, such as collagen-Ia, alkaline phospha-
tase (ALP), and osteocalcin (BGLAP) (Cohen, 2009; Dalle
Carbonare et al., 2012; Lian et al., 2006). Therefore,
RUNX2 initiates osteogenesis in a manner that is precisely
controlled temporally and spatially, and loss of RUNX2
expression at this early stage impairs osteogenic differen-
tiation in bone development (Otto et al., 1997; Cohen,
2013).
To better define the kinetics of osteogenic development
from hESCs and to more efficiently identify osteoprogeni-190 Stem Cell Reports j Vol. 4 j 190–198 j February 10, 2015 j ª2015 The Ator cells for clinical applications, we have generated a novel
reporter system for RUNX2 expression by utilizing the
RUNX2 P1 promoter driven expression of YFP. The P1 pro-
moter directs expression of the longest RUNX2 isoform
and is activated by developmental signaling pathways in
mesenchymal progenitor cells (Zhang et al., 2009). We
then stably introduced this RUNX2 P1 promoter-YFP
cassette with a constitutively active luciferase (luc) gene
for in vivo imaging into hESCs (H9 cell line). After verifying
the reliability of this reporter system, we tracked the osteo-
genic differentiation using this RUNX2-YFP-integrated H9
hESCs, evaluated the efficiency of such osteogenic differen-
tiation of hESCs, and tested the osteogenic phenotypes of
these differentiated cells in vivo.RESULTS
Integration of the Reporter System Does Not Alter
the Differentiation Pattern of hESCs
The RUNX2-YFP reporter was introduced to H9 hESCs us-
ing the Sleeping Beauty transposon system as previously
described (Wilber et al., 2007) (Figures S1A and S1B).
Because the engineered hESCs express luciferase (luc)
from a constitutive EF1a promoter, a highly enriched pop-
ulation of cells expressing the RUNX2-YFP construct was
achieved (more than 99% luc+ cells) by bioluminescent
imaging and repeated selection of luc+ cells (Figure S1C).
To test whether such genetic manipulation altered their
differentiation capability, unmodified H9 hESCs anduthors
Figure 1. Comparison of the Engineered and Unmodified hESCs
(A and B) Flow cytometric analysis of osteogenic differentiated unmodified hESCs (A) and RUX2-YFP-expressing hESCs (B) at passages 0–2.
Representative data from three independent experiments.
(C) qRT-PCR results of RUNX2 in undifferentiated hESCs (group 1), osteogenic differentiated hESCs at p5 (group 2), undifferentiated
RUNX2-YFP hESCs (group 3), and osteogenic differentiated RUNX2-YFP hESCs at p5 (group 4). GAPDH gene was used as internal control, and
the Ct value was normalized to group 1. Data presented as mean ± SEM, n = 3, *p < 0.05.
(D) Bright-field and fluorescent images of the unmodified and engineered H9 hESCs, in undifferentiated or differentiated conditions (scale
bar, 200 mm).engineered RUNX2-YFP-H9 hESCs were seeded on gelatin
pre-coated culture dishes and cultured in the osteogenic
differentiation medium (MSC medium, including 10%
characterized FBS, 1% P/S, 1% MEM-NEAA, 2 mM L-gluta-
mine in a-MEM, and osteogenic supplements [OSs] con-
sisting of ascorbic acid, dexamethasone, and b-glycero-
phosphate, termed MSC+OS medium) followed by serial
passaging. Analysis of typical MSC surface antigens and
YFP expression in the differentiated hESCs at passage 0,
1, and 2 demonstrated increasing CD73+ and CD105+ cells
over time, with comparable cell populations between
RUNX2-YFP hESCs and unmodified hESCs. YFP expression
was detected only in the engineered cells (Figures 1A
and 1B). To verify that this differentiation was generaliz-Stem Cellable for several clonal populations of the RUNX2-YFP-
expressing hESCs, the osteogenic differentiation of four
additional RUNX2-YFP-H9 hESC clones have been as-
sessed, all of which demonstrated similar differentiation
patterns (Figure S2A). Quantitative RT-PCR (qRT-PCR)
analysis of RUNX2 gene expression in the osteogenic
differentiated cells derived from the RUNX2-YFP hESCs
and unmodified hESCs showed comparable increase (Fig-
ure 1C). Morphologically, both hESC lines did not show
any obvious differences, with luciferase positive in the en-
gineered hESCs and YFP fluorescence observed only in the
differentiated RUNX2-YFP hESCs (Figures 1D and S1D).
Therefore, the similar differentiation capability of both
hESC lines allowed for the RUNX2-YFP-expressing hESCsReports j Vol. 4 j 190–198 j February 10, 2015 j ª2015 The Authors 191
Figure 2. Evaluation of the Reliability of YFP Reporter in Osteogenic Differentiated RUNX2-YFP hESCs
(A) Cell sorting of three cell populations in osteogenic differentiated hESCs at p1, based upon YFP expression intensity.
(B) Post-sort analysis of these three cell populations.
(C) qRT-PCR analysis of RUNX2 expression in the three cell populations along with undifferentiated cells and pre-sorted cells. GAPDH gene
was used as internal control, and the data presented here were normalized by the Ct value in undifferentiated group. Data presented as
mean ± SEM, n = 3, *p < 0.05.
(D) qRT-PCR results of additional osteogenic genes (SPARC and Collagen-Ia) in post-sorted YFP+ and YFP with undifferentiated and pre-
sorted cells. Data presented as mean ± SEM, n = 3, *p < 0.05.
(E) Flow cytometric analysis of YFP+ and CD34+ cell populations in hematopoietic differentiated hESCs in co-culture with M210 cells in 15%
FBS culture media on day 8.
For (A) and (B), representative results were shown from four biologically independent experiments. (E) is representative of three bio-
logically independent experiments.to be used in the following studies evaluating their osteo-
genic differentiation.
YFP Signal Faithfully Reports RUNX2Activation in the
Osteogenic Differentiated Cells
To verify the parallel expression of RUNX2 and YFP, we
isolated different cell populations in the osteogenic differ-
entiated hESCs based on the YFP expression intensity
and evaluated their RUNX2 gene expression by qRT-PCR.
Flow cytometric analysis confirmed the different YFP
expression intensities in the post-sorted cells (Figures 2A
and 2B). qRT-PCR results showed that the expression level
of RUNX2 gene corresponded to YFP intensity (Figure 2C).
These results demonstrated the fidelity of the YFP reporter192 Stem Cell Reports j Vol. 4 j 190–198 j February 10, 2015 j ª2015 The Ato monitor RUNX2 gene expression in the osteogenic
differentiated hESCs. We also evaluated Collagen-Ia and
SPARC genes in the sorted cell populations, which showed
similar expression patterns with the highest levels in YFP+
cell population (Figure 2D). To test the osteogenic speci-
ficity, we further evaluated YFP expression in these hESCs
cultured in hematopoietic differentiation condition des-
cribed in our previous study (Tian and Kaufman, 2008).
Flow cytometric analysis consistently showed that the
hematopoietic differentiated CD34+ hESCs are YFP
(Figure 2E). Taken together, these assessments demon-
strated the reliability of YFP expression to monitor
RUNX2 gene activation in the osteogenic differentiated
hESCs.uthors
Differentiated RUNX2-YFP-H9 hESCs Exhibit an
Osteogenic Phenotype In Vitro and In Vivo
Although considered a crucial transcription factor in bone
development, RUNX2 is also involved in early chondro-
genesis (Villavicencio-Lorini et al., 2010). To test the
phenotype of the differentiated cells, we first evaluated
chondrogenesis of these YFP+ cells at passage 5 by cell
aggregate formation in chondrogenic differentiation
medium. However, chondrogenic aggregates were not
observed by the YFP+ cells (data not shown). Next, the
phenotypes of the osteogenic differentiated hESCs and
bone-marrow mesenchymal stem/stromal cell (BM-MSC)-
derived osteoprogenitor cells were compared. This analysis
demonstrated that both cell populations express typical
MSC surface antigens and intracellular osteocalcin at
comparable levels, with no CD31, CD34, or CD45 expres-
sion (Figures 3A and S3A). As shown in Figure 3B, qRT-PCR
analysis demonstrated that the expression levels of osteo-
genic genes significantly increased in the cells cultured in
MSC+OS medium compared to cells cultured in MSC me-
dium alone. The increased levels of Coll-Ia and BGLAP
genes were significantly higher in BM-MSC-derived osteo-
progenitor cells than in the hESC-derived cells cultured
in MSC+OS medium, whereas a comparable increase of
RUNX2 and SPARC genes was found. These qRT-PCR re-
sults, which demonstrate elevated osteogenic gene expres-
sion in the differentiated hESC cultured in MSC medium,
are consistent with other studies (Arpornmaeklong et al.,
2010, 2011; Karp et al., 2006). As expected, the pluri-
potency gene OCT4 was reduced in both osteogenic-differ-
entiated cell populations (Figure S3B). Functional assays
demonstrated the YFP+ cells possess active osteogenic
potential comparable to BM-MSC-derived osteoprogenitor
cells. In contrast, there is minimal mineral deposition
produced by the YFP cell population (Figures S3C and
S3D).
To better define the kinetics of osteogenic development
in this system and to better define the developmental
stages of these differentiated cells, qRT-PCR analysis of
several early lineage-specific genes, BRACHYURY (T gene),
HAND2, FOXC1, and PAX3, in the osteogenic differenti-
ated hESCs was performed. These studies demonstrated
that BRACHYURY(T) gene expression level only transiently
increased, consistent with development of early mesoderm
(Ojala et al., 2012; Ramos-Mejia et al., 2010), followed by
differentiation of this population. In contrast, expression
of FOXC1 and PAX3 genes increased over time, suggesting
that the early mesodermal differentiation is followed by
subsequent differentiation favoring development of para-
xialmesoderm (indicated by FOXC1) and neural crest (indi-
cated by PAX3), with little differentiation into lateral plate
mesoderm (as minimal expression of HAND2 was seen).
These cells subsequently form mature osteoblasts after se-Stem Cellrial passaging, indicated by increased osteocalcin expres-
sion (BGLAP), in this defined osteogenic culture condition
(Figure S2B).
To assess the in vivo osteogenic potential, the differen-
tiated YFP+ hESCs cells were transplanted with gelatin
sponge into a critical size calvarial defect in an immunode-
ficient mouse model. After 3 months, no teratoma forma-
tion was identified post-implantation, and the cell survival
was demonstrated by the continued presence of luc+ cells
in the defect area. mCT results and histomorphometric
analysis showed that the bone volume in the defect area
repaired by cells in MSC+OS medium was significantly
higher than by cells inMSCmediumgroup,with the lowest
bone volume in the sponge only group (Figures 3C and
3D). Histological analysis of the healing tissue in MSC+OS
group demonstrated laminar bone structures with osteo-
cytes in a well-organized bone matrix and osteoblasts lin-
ing the surface of bone tissue. Hematoxylin and eosin
(H&E) staining and Masson’s Trichrome staining did not
show cartilaginous tissue (Figure 3E), which implies intra-
membraneous bone formation in the calvarial defect area.
Morphologically the newly formed bone tissue is different
from the adjacent calvarium, which is composed of cancel-
lous bone between cortical bones (Figure 3E). To identify
the origin of new bone, we used an osteocalcin (OC) anti-
body, which recognizes either human ormouse OC in oste-
oblasts or deposited in the bone matrix as demonstrated
in previous studies (Bielby et al., 2004; Hattori et al.,
2006; Sackstein et al., 2008). The immunostaining results
confirmed the species specificity of the anti-human OC
antibody (Figure S4A). The new bone tissue clearly stains
positive for human OC (Figure 3F), with an area that stains
for both human and mouse OC at the junction between
new bone tissues where presumably active osteoblasts
from both mouse and human are concentrated (Figures
3F and S4B). This OC distribution pattern is consistent
with the histological finding that osteoblasts that produce
OC are located in areas of new bone development, whereas
osteocytes that produce little OC reside in area of more
mature bone. Additional anti-human MHC-I staining also
demonstrated similar distribution of human cells in the
area of new bone formation (Figure S4C). These results
confirm osteogenic potential of these implanted hESC-
derived YFP+ osteoprogenitor cells. In addition to engraft-
ment and development of human osteoblasts/osteocytes,
it is also likely that the implanted human cells induced
proliferation of mouse osteoblasts that contributed to
the repair, as seen in similar models (Kuhn et al., 2014).
hESC-derived MSCs are known to produce cytokines and
growth factors that might induce endogenous bone repair
(Kopher et al., 2010; Kimbrel et al., 2014), though specific
agents that are active in this model need further elucida-
tion in future studies.Reports j Vol. 4 j 190–198 j February 10, 2015 j ª2015 The Authors 193
Figure 3. Characterization of Osteoprogenitor Cells Derived from RUNX2-YFP hESCs In Vitro and In Vivo
(A) Flow cytometric analysis of the cell-surface markers and osteocalcin (red, undifferentiated cells; blue, osteogenic differentiated cells)
in osteogenic differentiated hESCs at p5 (RUNX2-YFP hESCs derived) and in BM-MSCs cultured in osteogenic medium for 2 weeks (BM-MSCs
derived). Representative data are from three independent experiments.
(B) qRT-PCR analysis of the osteogenic gene expression in the undifferentiated hESCs (group 1), the hESCs differentiated in MSC medium
(group 2) or MSC+OS medium (group 3), and BM-MSCs in MSC medium (group 4) or MSC+OS medium (group 5). GAPDH gene was used as
internal control, and data presented here were normalized by Ct value in group 1. Data summarized as mean ± SEM, n = 3, *p < 0.05.
(C) Morphological evaluation of mouse calvarial defect repair. Upper panels are superimposed bright-field and bioluminescent images to
demonstrate cell survival and location in the calvarial defect area. Middle panels are 3D reconstructed micro-CT images (the box in group
Sponge+MSC+OS indicates where the histology images were acquired). Lower panels are cross-sectional micro-CT images.
(D) Quantitative evaluation of bone volume in the repaired area of calvarial defect by micro-CT. Data presented as mean ± SEM, n = 4 in
each group, *p < 0.02.
(E) Histological evaluation of the healing tissue in mouse calvarial defect repaired by cells in group Sponge+MSC+OS. The upper panel is
hematoxylin and eosin (H&E) staining, scale bar, 600 mm; the bottom panel is Masson’s Trichrome staining, scale bar, 600 mm; the middle
panels are higher power views of the H&E staining (left, scale bar, 38 mm) and Trichrome staining (right, scale bar, 38 mm). These higher
power images show the junction area of healing tissue. *Area of new bone growth derived primarily from hESC-derived cells; (arrowheads)
osteoblasts showing area of new bone development; (arrows) osteocytes in area of more mature mineralized bone.
(F) Immunohistochemical staining of human osteocalcin (red) versus mouse osteocalcin (blue) in the junction area of the repaired mouse
calvaria (same region as in middle panels of Figure 3E) (scale bar, 38 mm).
See also Figure S4.
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Figure 4. The Role of OS in Osteogenic Differentiation of RUNX2-YFP hESCs
(A) Flow cytometric analysis of cells differentiated in 10%FBS MSC media, with or without OS, at passage 1, 3, and 5. Representative results
from two independent experiments.
(B) Flow cytometric analysis of the osteogenic differentiated cells through passage 4. Representative data from three independent ex-
periments.
(C and D) Evaluation of cell differentiation in serum-free condition with or without OS, in the presence or absence of BMP2 or FGF9, at day
10. KOSR, 5% KOSR in place of 10% FBS in MSC media; BMP2, 50 ng/ml; FGF9, 10 ng/ml. Data are presented as mean ± SEM, n = 3, *p < 0.05.Homogenous Osteoprogenitor Cell Population
Derived byOS Treatment of hESC-Derived CD73+ Cells
To test the role of OS in the osteogenic differentiation of
hESCs, we compared the differentiation of hESCs in MSC
medium with or without OS at different passages. We
found that serum (FBS) promoted a CD105+ population
as well as YFP+ population in hESCs. Addition of OS mark-
edly increased YFP+ cell population, especially in the early
stage (P1), and enhanced YFP expression level in the YFP+
cells (Figure 4A), suggesting that OS in serum-containing
medium can significantly boost osteogenic differentiation
of hESCs (Figure 4A). These results, combined with the
qRT-PCR data (Figure 3B), suggest the superior osteogenic
capability may quantitatively and qualitatively contribute
to better in vivo bone formation of the cells in theMSC+OS
group (Figure 3D).
Flow cytometric analysis of the osteogenic differentia-
tion of hESCs inMSC+OSmediumdemonstrated a homog-Stem Cellenous YFP+ population at passage 4 after serial subculture
of hESCs in the osteogenic medium (Figures 4B and S2C).
Persistent YFP expression suggests that the differentiated
hESCs in osteogenic conditions have committed to an oste-
ogenic lineage. Because essentially all YFP+ cells are CD73+
butnot all CD73+ cells are YFP+ in early passages (Figure 4B),
these studies suggest that CD73+ cells might serve as the
precursors of CD73+YFP+ osteogenic cells.
Next, we tested whether OS may generate YFP+ cells
directly without serum-induced differentiation of hESCs
and the role of some osteogenic factors in the generation
of YFP+ cell population. We cultured RUNX2-YFP hESCs
with or without OS in serum-free medium overnight fol-
lowed by addition of BMP2 or FGF9 for 10 days. Flow cyto-
metric analysis of the differentiated cells showed that cells
did not express either CD73 or YFP when cultured in
knockout serum replacement (KOSR) or FGF9+KOSR me-
dium, and addition of BMP2 to KOSR induced obviousReports j Vol. 4 j 190–198 j February 10, 2015 j ª2015 The Authors 195
increase of CD73+ but not YFP+ population; addition of OS
induced YFP expression only in the BMP2-treated cells, not
in the other two groups (Figures 4C and 4D). This short-
term analysis in serum-free differentiation media suggests
that OS itself could not induce osteogenic differentiation
of hESCs unless combined with BMP2, which induces
CD73+ cell population. Similarly, BMP2 is not sufficient
to induce osteogenic differentiation of hESCs unless com-
bined with OS tomediate development of CD73+YFP cells
to CD73+YFP+ osteogenic progenitor cells.DISCUSSION
hESCs demonstrate the potential to serve as a starting cell
population for bone regeneration, and previous studies
report effective differentiation of hESCs to osteogenic line-
age (Arpornmaeklong et al., 2010; Ka¨rner et al., 2009).How-
ever, it remains important to better define how to obtain
homogeneous osteogenic progenitor cells from hESCs.
Our studies utilize a novel RUNX2 (P1)-YFP reporter system
to monitor osteogenic differentiation of hESCs. Combined
in vitro and in vivo studies validate the fidelity of this sys-
tem to monitor the osteogenic differentiation and identify
the osteogenic cell population derived from hESCs.
Direct differentiation of hESCs has been reported to
generate osteogenic cells with comparable osteogenic activ-
ity as the cells derived from hBM-MSC or from hESC-
derived MSCs (Arpornmaeklong et al., 2011). Here, we
simultaneously evaluated expression of RUNX2 and MSC
surface markers to monitor the osteogenic development
of hESCs in vitro. The flow cytometry data, gene expression
results and in vivo study consistently demonstrated the
osteogenic activity in a fraction of hESC-derived cells
cultured in serum with no OS. These results are in agree-
ment with previous studies (Arpornmaeklong et al., 2011;
Harkness et al., 2011; Kuhn et al., 2014). While addition
of OS to serum enhances osteogenic differentiation of
hESCs to produce a homogenous osteoprogenitor popula-
tion, OS itself cannot induce such differentiation prior to
development of CD73+ cells from hESCs allowed to differ-
entiate with either serum or BMP2 in vitro. These results
suggest that CD73+ cells in the differentiated hESCs might
serve as an intermediary cell population to generate osteo-
progenitor cells, which provides a plausible mechanism as
to why addition of OS at day 14 may dramatically increase
bone nodule formation by ESCs in vitro (Bielby et al., 2004;
Buttery et al., 2001). Therefore, the term ‘‘direct osteogenic
differentiation’’ needs to be cautiously usedwhenhESCs are
directly exposed to osteogenic differentiation condition.
The in vitro study of BMP2 provides additional insight
and further demonstrates the utility of this RUNX2-YFP re-
porter system. Similar to a short-term study on the effect of196 Stem Cell Reports j Vol. 4 j 190–198 j February 10, 2015 j ª2015 The ABMP2 in humanMSCs (Osyczka et al., 2004), we also found
that BMP2 does not activate RUNX2, indicated by no YFP
expression. However, BMP2 does increase CD73+ cell pop-
ulation in hESCs cultured in serum-free conditions. These
data suggest BMP2 alone does not induce osteogenic differ-
entiation but may promote the generation of CD73+ cells
first and then synergistically facilitates osteogenic differen-
tiation when combined with OS in serum-free condition.
Of course, additional detailed long-term studies will be use-
ful to further define the osteogenic factors that mediate
osteogenic development.
In conclusion, this RUNX2-YFP reporter system is a reli-
able tool to monitor the osteogenic differentiation of
hESCs. It provides a new method to understand the differ-
entiation stages during bone development in a human sys-
tem. Likewise, this system is useful to isolate early human
osteogeneic cells and to further optimize differentiation
protocols to better define osteogenic development factors
for both hESCs and induced pluripotent stem cells (iPSCs).EXPERIMENTAL PROCEDURES
Creation of Vector and the Stable Cell Line and
Induction of Osteogenic Differentiation of hESCs
hESCs were cultured and induced osteogenic differentiation
according to the protocol in Dr. Krebsbach lab (Arpornmaeklong
et al., 2011). See Supplemental Experimental Procedures for addi-
tional details.
Flow Cytometric Analysis and Fluorescent Imaging
Single-cell suspension of differentiated cells was prepared as previ-
ously described (Kopher et al., 2010). See Supplemental Experi-
mental Procedures for additional details.
Real-Time RT-PCR Analysis
Total RNA was abstracted and reverse transcribed into cDNA.
Quantitative real-time RT-PCRs were performed. See Supplemental
Experimental Procedures for additional details.
Implants Preparation and Surgical Procedure
The differentiated H9-RUNX2-YFP cells at p56 were used for
in vivo study. See Supplemental Experimental Procedures for addi-
tional details.
Bioluminescent Imaging and microCT Measurement
of Defect Repair In Vivo
The bioluminescence images of the implanted cells were visual-
ized, and the bone formation of calvarial defect was assessed using
microtomography. See Supplemental Experimental Procedures for
additional details.
Histological and Immunohistochemical Study
Histological evaluation of the healing tissue in mouse calvarial
defect area was performed according to our previously reporteduthors
protocol (Kopher et al., 2010). See Supplemental Experimental Pro-
cedures for additional details.
Statistical Analysis
Each experiment was repeated biologically three times indepen-
dently, if not stated otherwise. As noted in the figure legends,
‘‘n’’ stands for the number of biologically independent experi-
ments. Results were presented as mean ± SEM. Statistic analysis
was performed using Microsoft Excel and Prism. One-way or
two-way ANOVA was used for multiple comparisons. p values
was calculated by two-tailed Student’s t test, and the significant dif-
ference was defined by p < 0.05, as indicated by asterisk.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2015.
01.008.
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